Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17549652 | 0.91 | ALDH1A1 (0.73) | ALDH1A1KMT2AGFERL3MBTL1L3MBTL3 | |
| SCHEMBL2834503 | 0.86 | ALDH1A1 (0.79) | ALDH1A1KMT2AGFERADRA1DADRA1A | |
| SCHEMBL13089690 | 0.86 | L3MBTL1 (0.54) | L3MBTL1L3MBTL3KDM4E | |
| SCHEMBL5182996 | 0.85 | ALDH1A1 (0.76) | ALDH1A1KMT2AGFERADRA1DADRA1A | |
| SCHEMBL11790502 | 0.84 | HTR1A (0.69) | ALDH1A1KMT2AADRA1AL3MBTL1DRD2 | |
| SCHEMBL10603564 | 0.82 | ALDH1A1 (0.81) | ALDH1A1KMT2AGFERADRA1DADRA1A | |
| SCHEMBL7645836 | 0.82 | ALDH1A1 (0.81) | ALDH1A1KMT2AGFERADRA1DADRA1A | |
| SCHEMBL13089686 | 0.81 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1L3MBTL3SIGMAR1 | |
| SCHEMBL7393089 | 0.81 | ADRA1D (0.62) | ADRA1DADRA1AADRA1BL3MBTL1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10606849 | 0.81 | ALDH1A1 (0.82) | ALDH1A1KMT2AGFERADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377555-B1 | A DIOXINO[2,3-G]QUINOLINE-9-CARBOXYLIC ACID DERIVATIVE AS NK3 RECEPTOR ANTAGONIST | GLAXOSMITHKLINE SPA (IT) | 2007-01-24 | — | — | EP | disclosed |
| US-20050182093-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. | 2005-08-18 | — | — | US | disclosed |
| US-20040152730-A1 | Novel compounds | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | disclosed |
| EP-1377555-A1 | NOVEL COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002083645-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182093-A1 | Novel compounds | SLC10A1, AVPR2, REN | ALDH1A1 1675/4885KMT2A 4427/4885GFER 4800/4885 |
| US-20040152730-A1 | Novel compounds | SLC10A1, AVPR2, REN | ALDH1A1 1675/4885KMT2A 4427/4885GFER 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.